Then let me introduce:

Juhl Wind, Inc. (JUHL)

Juhl Wind Partners with Honeywell on U.S. Department of Energy Project

JUHL and Honeywell International have been awarded a United States Department of Energy program to test the application of a proprietary Honeywell remote data monitoring system for turbine maintenance. JUHL will be providing the field application, installation, monitoring and support on a number of installations around the United States.   Read the full release here

I can only assume that Honeywell did their due diligence before bringing JUHL into partnership with them.  I think that it says a great deal about JUHL that a company with $31 Billion in revenues (Honeywell, of course) is partnered with a company that posted revenues in the area of $1.5 Million (ahem, JUHL).

But, Honeywell won’t be doubling or tripling revenues like JUHL is expected to do in 2010!

Why would they pick JUHL?

JUHL has been HIGHLY successful in the development and management of wind and solar projects.  How many alternative energy companies that you know have this track record?

·         The successful development (and operation) of 14 wind farms currently generating 117 Megawatts (MW) of energy
·         Engaged in the development of 28 wind farms totaling an additional 450 megawatts of community wind power systems.

Oh, that’s why!

JUHL is a revenue-producing, vertically-integrated, wind and solar company that is establishing a strong presence in both the solar and wind industries in the United States and Canada.  JUHL are specialists in what they call “Community-based” wind power generation and management which provides for local ownership of medium-to-large scale wind farms.

JUHL generates revenues from the full range of services it provides to both solar and wind projects:

· Feasibility Studies

· Full-scale Development Management

· Planning, citing, engineering and financial analysis, project financing and construction

· Construction Management

· Long-term Operations and Maintenance

· Equity Ownership

One last thing:

The chart offers a great setup for possible gains:

· The stock appears to be sitting on support at around $1.60
· Current volume is light, but JUHL is a “float stock” — meaning there aren’t many shares out there in the public’s hands.
· MACD is bearish, but is not trending significantly.  It could turn positive quickly if volume comes back into the stock.
· The selloff over the last few days has lessened any overbought pressure as indicated by the stochastics

As I mentioned in my earlier email, “I liked it then, but I love it now.” JUHL is, to my mind, a well run company.  They have experienced management, growing revenues, cash-in-the bank (over $5MM) and NO DEBT.  This Honeywell deal could be a “game changer” for them and is confirmation that they are on the right track.

Do your own due diligence and be ready to trade.

Trade like you mean it!

Jeffrey Dean
Editor

—————————————————————————————————–

Exact Sciences Corp. (EXAS) develops deoxyribonucleic acid (DNA)-based technologies for use in the detection of cancer. The Company has selected colorectal cancer as the first application of its technologies. The Company has licensed certain of its technologies, on an exclusive basis through December 2010, to Laboratory Corporation of America Holdings (LabCorp). LabCorp developed and commercially offered PreGen-Plus, its first generation non-invasive stool-based DNA colorectal cancer screening service for the average-risk population.

The Company was founded in 1995 and is based in Madison, Wisconsin.

Share Statistics (10-Mar-10)			FY 2007	FY 2008	% Chg	Q3 2008	Q3 2009	% Chg
Symbol	EXAS	Revenue, $Mn	1.80M	-0.87M	100.0%	0.00M	1.26M	100.0%
Current price	$4.85	Gross marg.	97.3%	100.1%	2.9%	n/a	96.3%	n/a
52wk Range:	$0.77-5.25	Oper. margin	-714.5%	1150.3%	261.0%	n/a	-85.7%	n/a
Avg Vol (3m):	125,515	Net margin	-664.4%	1119.5%	268.5%	n/a	-82.5%	n/a
Market Cap.	170.2M
Dil. Shares Outst.	35.6M	EPS, $	-0.44	-0.36	18.2%	-0.66	1.26	290.9%

Source: Reuters.com, SEC Filings.

Financial Summary

EXAS reported total revenues of $1.2 million for the fourth quarter of 2009, compared to total revenues of ($109,000) during the same period of 2008. Fourth-quarter 2009 total revenues increased due to the quarterly non-cash allocation that resulted from a 2009 intellectual property license transaction. Total revenues for the year ended Dec. 31, 2009, were $4.8 million, compared to total revenues of ($867,000) for the prior year.

EXAS reported a net loss of ($1.8) million, or ($0.05) a share, for the fourth quarter of 2009. The Company had a net loss of ($2.1) million, or ($0.08) a share, for the same period of 2008. EXAS’s net loss for the year ended Dec. 31, 2009, was ($9.1) million, or ($0.28) a share, compared to ($9.7) million, or ($0.36) a share, for the prior year.

Operating expenses for the fourth quarter of 2009 were $3.0 million, compared to $2.0 million for the same period of 2008. Operating expenses for the year ended Dec. 31, 2009, were $13.9 million, compared to $9.1 million for the same period of 2008.

EXAS ended the fourth quarter of 2009 with cash, cash equivalents and marketable securities of $24.3 million, compared to $4.9 million at Dec. 31, 2008.

Financial Strength (10-Mar-2010)	Company	Industry	Sector	S&P 500
Quick Ratio (MRQ)	2.82	6.21	2.62	0.83
Current Ratio (MRQ)	3.82	6.69	3.13	0.99
Long-Term Debt to Equity (MRQ)	16.31	28.13	25.47	141.11
Total Debt to Equity (MRQ)	16.13	32.84	33.17	201.66

Source: Reuters.com, SEC Filings.

Analyst Consensus

This is the consensus forecast among 2 polled investment analysts. Against the Exact Sciences Corp. company.

The 2 analysts offering 12-month price targets for EXAS have a median target of 5.50, with a high estimate of 6.00 and a low estimate of 5.00. The median estimate represents a 25.86% increase from the last price of 4.37.

Source: www.ft.com

Consensus Estimates Analysis

Source: http://www.reuters.com/finance/stocks/financialHighlights?symbol=EXAS.W

Investment Highlights

EXAS focuses on launching FDA-cleared colorectal cancer screening tests to detect both pre-cancer and cancer to promote cancer prevention.

The Company has exclusive intellectual property to protect its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.

Although the science behind stool-based DNA screening is very sophisticated, the specimen collection process is very simple. Sample collection requires:

• No bowel preparation
• No medication or dietary restrictions
• No lost time from a patient’s daily routine

By simplifying the routine screening process, stool-based DNA screening directly addresses patient non-compliance issues. As a result, more patients may be safely screened without the discomfort and inconvenience associated with invasive procedures. Greater compliance, in turn, may lead to earlier detection and potentially the prevention of colorectal cancer. Colorectal cancer is the second-leading cause of cancer deaths, according to the American Cancer Society. Almost 150,000 new cases of colorectal cancer are diagnosed and approximately 50,000 people die from the disease every year.

Source: http://www.exactsciences.com/

Technical Analysis

Source: http://stockcharts.com

EXAS is trading above its 50-day moving average. This is considered to be the sign of a bullish trend. There is added weight to this indication because the moving average is rising and suggests that there has been buying interest in this stock.

EXAS is trading above its upper Bollinger Band. Relative to recent price action, the stock is currently overextended and due for either a pause or retracement.

The MACD for EXAS currently indicates a strong bullish signal for two reasons. First, the MACD is above the signal line, a 9-day moving average. Second, the MACD is above 0, which implies that the underlying moving averages are trending higher.

Comparative Analysis

Source: Thomson Financial

Insider Trading Activity

NET SHARES PURCHASE ACTIVITY Inside Purchases - Last 6 Months
	Shares	Transaction
Purchases	2,500	1
Sales	n/a	0
Net Shares Purchased (Sold)	2,500	1
Total Insider Shares Held	10.09M	n/a
% Net Shares Purchased (Sold)	0.0%	n/a

Net Institutional Purchases - Prior Qtr to Latest Qtr
	Shares
Net Shares Purchased (Sold)	(906,559)
% Change in Institutional Shares Held	(11.5%)

Source: Yahoo Finance

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

]]> http://investorsoup.com/2010/03/stock-alert-for-exact-sciences-corp-exas/feed/ http://investorsoup.com/2010/03/snwt-is-ready-for-liftoff/ http://investorsoup.com/2010/03/snwt-is-ready-for-liftoff/#comments Wed, 10 Mar 2010 14:29:30 +0000 Jeffrey Dean http://investorsoup.com/?p=4109 On the Road to Off-Road Profits!

Good Morning!

I think it’s time to say hello again (for those of you who’ve been with me awhile) to one of our past winners…

San West, Inc. (SNWT)

SNWT is a retailer of premier off-road recreational vehicles in Southern California and the Western United States as well as a leading supplier in the off-road recreational vehicle arena through aftermarket parts, accessories and its highly successful vehicle repair and maintenance center.

Yes, all that of course is well known—but what isn’t is that…

SNWT has been posting some great numbers lately and has a chart setup that demands our attention—once again!

While its competitors are “pulling in their horns”, SNWT is aggressively expanding its marketing reach through both organic growth and strategic acquisitions.

Beginning with its first acquisition, Buggy World in late 2008, SNWT has been busy expanding its brands, increasing its web presence and adding affiliates—and, of course, market share!

· SNWT’s wholly owned subsidiary, Letz Go Racing Off-Road Center, is a leading company that develops aftermarket, high-performance accessories for off-road all-terrain vehicles, such as Go Karts.

· CountyImports.com, the second largest online retailer in the off-road market, is also a wholly-owned subsidiary of SNWT and has created two very profitable websites that sell off-road vehicles and parts directly to consumers

· Buggy World, SNWT’s first acquisition, is an established retailer of off-road buggies, buggy parts and accessories with multiple locations in Southern California

· SNWT is the exclusive TrophyKart dealership for San Diego County

· SNWT has also acquired sales and marketing rights for leading off-road sporting brands Fox Racing, Joiner, and Thor.

· And just last week—SNWT announced the launch of www.ScootSpeedShop.com a new e-commerce website selling high-performance parts for on-road Scooters and off-road recreational vehicles (ORVs).

A triple revenue gainer in the making!

SNWT recently announced revenue guidance for 2010 of between $6 Million and $8 Million!

Hitting even the lower range of that forecast means SNWT is expecting to TRIPLE Revenues in 2010.

Wait, the news gets even better!

SNWT has also announced that it has obtained $10,000,000 in equity financing from an institutional investor.

Frank Drechsler, CEO of SNWT, summed up the impact of this financing on the company as follows:

“This significant financing arrangement gives San West and its subsidiaries access to growth capital, enabling us to accelerate our growth strategy and implement additional marketing initiatives to take full advantage of the increasing demand for personal motorsports vehicles, parts, services and accessories,”

A strong 2010 revenue forecast plus $10 MILLION in new financing makes SNWT a company worth watching in my opinion!

And now this…

SNWT’s chart could signal a reversal in trend…

· The candles seems to indicate that its downtrend is losing steam.

· Confirmation of this can be seen in the Stochastics which are giving a strong oversold signal

· However, the MACD has crossed and is entering bearish territory.  If the stock breaks below 11 cents, that might signal a continued downtrend.  But I don’t think that will happen, nevertheless, watch for any break below that number.

· Volume is still very strong

A growing player in a $31 BILLION industry!

SNWT is part of a $31.5B industry according the The Motor Industry Council.

Bottom line: I like what I’m seeing from SNWT and suggest you do your Due Diligence quickly.

SNWT has been very volatile in the past—which is great for us traders—so I don’t want you to miss any of the price action.

Good luck and good trading!

Jeffrey Dean

Editor

_________________________________________________________________________________

]]> http://investorsoup.com/2010/03/snwt-is-ready-for-liftoff/feed/ http://investorsoup.com/2010/03/stock-alert-for-indocan-resources-inc-idcn/ http://investorsoup.com/2010/03/stock-alert-for-indocan-resources-inc-idcn/#comments Wed, 10 Mar 2010 07:52:02 +0000 Jeffrey Dean http://investorsoup.com/?p=4092 Indocan Resources Inc. (OTC PK: IDCN)

Indocan Resources Inc. (IDCN) is a Montana-based holding company primarily invested in the natural resources industries. The Company has both oil & gas interests, as well as metals exploration and mining interests. IDCN recently began an exploration program in NW Ontario on a known gold property and said it will publish geologist written information and test results each week or so as the program progresses.

Share Statistics (09-Mar-10)			FY 2007	FY 2008	% Chg	Q3 2008	Q3 2009	% Chg
Symbol	IDCN	Revenue, $Mn	n/a	n/a	n/a	n/a	n/a	n/a
Current price	$0.002	Gross marg.	n/a	n/a	n/a	n/a	n/a	n/a
52wk Range:	$0.0001-0.0028	Oper. margin	n/a	n/a	n/a	n/a	n/a	n/a
Avg Vol (3m):	n/a	Net margin	n/a	n/a	n/a	n/a	n/a	n/a
Market Cap.	2.6M
Dil. Shares Outst.	1.2B	EPS, $	n/a	n/a	n/a	n/a	n/a	n/a

Source: Reuters.com, SEC Filings.

Financial Summary

Source: Reuters.com, SEC Filings.

Analyst Consensus

No chart available.

Source: www.ft.com

No consensus analysis data available.

Source: http://www.reuters.com/finance/stocks/financialHighlights?symbol=IDCN.PK

Investment Highlights

IDCN’s board of directors recently announced that its Oil Patch efforts are moving forward as anticipated. The Company has committed to 50% of an Oil & Natural Gas project in Pennsylvania whereby Indocan Resources Oil & Gas LP will invest with funds from investors, the Limited Partners, up to $593,000 in a 20 well plan that yields 60% NRI to the Company. These wells will co-produce oil and gas. Surrounding area wells are producing with a zero water cut and IDCN expects the same. Drilling should commence in April with cash flow to begin in July if all is on schedule.

The Company also recently announced that its Hockey Stick property in NW Ontario is moving forward with draft options and operating agreements on the table from lawyers with final agreements expected to be executed in the near future. IDCN geologists are preparing a sampling program and other plans to be submitted to the joint venture for examination and ultimately approval. At least two other properties with similar prospects to Hockey Stick are being considered by management and have a reasonable proximity to each other and have similar prospects as Hockey Stick.

Source: http://www.indocan.com/

Technical Analysis

Source: http://stockcharts.com

IDCN is trading above its 50-day moving average. This is considered to be the sign of a bullish trend. There is added weight to this indication because the moving average is rising and suggests that there has been buying interest in this stock.

IDCN’s recent volatility has been greater than normal. This is evidenced by the increased distance between the upper and lower Bollinger Bands. These bands measure volatility using standard deviation and a large width is due to high volatility. Additionally, IDCN is trading above its upper Bollinger Band. Relative to recent price action, the stock is currently overextended and due for either a pause or retracement.

The MACD for IDCN currently indicates a strong bullish signal for two reasons. First, the MACD is above the signal line, a 9-day moving average. Second, the MACD is above 0, which implies that the underlying moving averages are trending higher.

Insider Trading Activity

NET SHARES PURCHASE ACTIVITY Inside Purchases - Last 6 Months
	Shares	Transaction
Purchases	n/a	n/a
Sales	n/a	n/a
Net Shares Purchased (Sold)	n/a	n/a
Total Insider Shares Held	n/a	n/a
% Net Shares Purchased (Sold)	n/a	n/a

Net Institutional Purchases - Prior Qtr to Latest Qtr
	Shares
Net Shares Purchased (Sold)	n/a
% Change in Institutional Shares Held	n/a

Source: Yahoo Finance

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

]]> http://investorsoup.com/2010/03/stock-alert-for-indocan-resources-inc-idcn/feed/ http://investorsoup.com/2010/03/stem/ http://investorsoup.com/2010/03/stem/#comments Tue, 09 Mar 2010 22:11:49 +0000 Jeffrey Dean http://investorsoup.com/?p=4095 StemCells, Inc. (STEM) has been the poster child for the stem cell industry since late 2008.  It has made many people rich speculating on the ups and downs of this particular stock.  With its ticker symbol that seems to represent the entire industry, investors and traders have made this a very popular stock.

Their is an old saying that says “when the media sneezes, the whole world catches cold”.  That has certainly been a huge factor in the rise (and fall) of STEM and other stem cell stocks.  Stem cell hysteria has hit several times over the past few months with investor interest being peaked by media hype.

Here is a description of the company from Yahoo! Finance:  StemCells, Inc., a clinical-stage biotechnology company, focuses on the research, development, and commercialization of products derived from stem cell technologies. It focuses on developing cell-based therapeutics to treat diseases of the central nervous system and liver.

Most stem cell companies that I have seen are very far away from making their particular take on the propagation or use of stem cells profitable.  STEM is no different.  It does have some revenues, but expenses far outweigh revenues.  The good news for STEM is that management has used all of this hype and interest in stem cell stock pay dividends in the form of equity raises and fundraising.  STEM has an impressive cache of cash (over $28MM as of 9-30–09), but at a $7MM quarterly burn rate that cash will last them a year.  STEM will probably never seen penny stock land again and I could see it upgrading its listing in the future.

Chart analysis:

STEM has an interesting chart that bears watching.  See my annotations below.

The stock appears to be basing at this level and performance of this stock could depend solely on what news comes out regarding stem cells in the next few weeks.

For those traders who want to be ready for the next stem cell explosion, here are some tickers that you should hold on to:

ACTC  * ALXN * AOLS * ARIA * ASTM * BHRT * BMSN * BTIM * CBAI * CCEL * CELG * CRIS * CUR * DNDN * GERN * IART * INCR * ISCO * KOOL * MCET * MEDS * OCHT * OSTE * OSIR * PKI * PPMD * PSTI * SPPI * STEM * VODG

I have previously blogged ACTC, ARIA, CBAI, PSTI and now STEM.

There is a strong short sentiment about STEM with the latest Yahoo! stats showing a short percentage of 15.6% as of 2-12-10

In my opinion, STEM has a nice setup.  Any strength in the stock and the short squeeze will only accelerate the gains.  The stock should be avoided on any break below the current support of $1.16

Good luck and good trading,

Jeffrey Dean

Editor

___________________________________________________________________________

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Neither InvestorSoup.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Newport Digital Technologies Inc. (NPDT), formerly International Food Products Group Inc., is a development-stage company. The Company is focused on the marketing and distribution of technology products and was previously engaged in the food business. The Company has underway the development, positioning and initial marketing of several different wireless technology solutions. The Company has developed, through alliances with other companies, a portfolio of competencies in various wireless technologies, such as radio frequency identification (RFID), WiMax, digital signage/ light emitting diode (LED) lighting, and security and surveillance solutions.

Newport Digital Technologies Inc. was founded in 1996 and is based in Newport Beach, California.

Share Statistics (08-Mar-10)			FY 2007	FY 2008	% Chg	Q3 2008	Q3 2009	% Chg
Symbol	NPDT	Revenue, $Mn	0.0K	0.0K	0.0%	0.0K	0.0K	0.0%
Current price	$0.022	Gross marg.	n/a	N/a	n/a	n/a	n/a	n/a
52wk Range:	$0.0095-0.058	Oper. margin	n/a	N/a	n/a	n/a	n/a	n/a
Avg Vol (3m):	n/a	Net margin	n/a	n/a	n/a	n/a	n/a	n/a
Market Cap.	27.9M
Dil. Shares Outst.	1.3B	EPS, $	0.00	0.00	0.0%	0.00	0.00	0.0%

Source: Reuters.com, SEC Filings.

Financial Summary

Results of Operations for the three-month periods ended December 31, 2009, and 2008:

Net sales for the six-month period ended December 31, 2009, and 2008, were $0. NPDT had no sales in the current period while gearing up with its new business plan.

The Cost of Sales for the six-month period ended December 31, 2009, and 2008, was $0.

Engineering Expense for the six-month period ended December 31, 2009, was $291,883 compared to $0.0 in the prior period. The Company discontinued its food operations and started to devote its attention to developing technologies in December 2008.

General and Administrative expenses for the six-month period ended December 31, 2009, were $7,645,620 compared to $387,782 in the same period in 2008. In order to restructure the new business it was imperative to increase consultants and professional fees $5,881,000. The Company hired high level, industry experts to operate the Company, which increased officer salaries to $285,400 and office salaries to $372,116. Investor relations increased to $410,973 in an effort to keep its shareholder base informed during the transition. Travel and engineering were $91,000 and $291,000 respectfully.

NPDT has experienced net losses of $7,709,683 and $201,341 for the six months ended December 31, 2009 and 2008, respectively. At December 31, 2009, it had $505 in cash and $115,000 in non-refundable deposits. As a development stage company in its new field of endeavor, it currently does not have revenue producing operations, and must sustain operations through equity and debt financing.

Financial Strength (08-Mar-2010)	Company	Industry	Sector	S&P 500
Quick Ratio (MRQ)	0.14	2.45	1.46	0.83
Current Ratio (MRQ)	0.14	2.85	1.73	0.99
Long-Term Debt to Equity (MRQ)	–	21.89	27.32	137.56
Total Debt to Equity (MRQ)	–	36.03	43.30	197.84

Source: Reuters.com, SEC Filings.

Analyst Consensus

No chart available.

Source: www.ft.com

No consensus analysis data available.

Source: http://www.reuters.com/finance/stocks/financialHighlights?symbol=NPDT.OB

Investment Highlights

NPDT announced last week that it has developed and launched its first leading-edge wireless LED digital signage solution that offers wireless high definition video and audio streaming that is compatible with Wifi, WiMax and nationwide 3G networks offered from companies such as AT&T.

The LED digital signage solution will provide modular and customizable display sizes from 50″ to stadium-size displays. The solution will also encompass a digital content management and delivery system that will allow users to deliver digital content from anywhere by connecting a laptop to a signage display via the Web.

RFID (Radio Frequency Identification) technologies open up an exciting new world of possibilities for businesses and governments to increase the efficiency of their operations and develop innovative new applications and services by allowing them to securely capture, track and manage their critical data in real-time. The data may come from pallets in a warehouse, goods in a shopping cart, ID tags on students, patients, inmates and even from passports, credit cards and other documents.

Source: http://www.newportdt.com/

Technical Analysis

Source: http://stockcharts.com

NPDT is below its 50-day moving average. This bearish sign is even more significant because the moving average is also trending lower.

NPDT’s recent volatility has been greater than normal. This is evidenced by the increased distance between the upper and lower Bollinger Bands. These bands measure volatility using standard deviation and a large width is due to high volatility. Additionally, NPDT is trading near its upper Bollinger Band. This suggests that the stock price is high relative to its recent price action.

NPDT’s MACD is currently indicating a weak bullish signal. Although the MACD is trending above the signal line, the indicator is still below 0, which suggests that the underlying moving averages are bearish.

Comparative Analysis

Source: Thomson Financial

Insider Trading Activity

NET SHARES PURCHASE ACTIVITY Inside Purchases - Last 6 Months
	Shares	Transaction
Purchases	n/a	0
Sales	n/a	0
Net Shares Purchased (Sold)	n/a	0
Total Insider Shares Held	186.88M	n/a
% Net Shares Purchased (Sold)	0.0%	n/a

Net Institutional Purchases - Prior Qtr to Latest Qtr
	Shares
Net Shares Purchased (Sold)	n/a
% Change in Institutional Shares Held	n/a

Source: Yahoo Finance

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

]]> http://investorsoup.com/2010/03/stock-alerts-for-newpport-digital-technologies-inc-npdt/feed/ http://investorsoup.com/2010/03/almealert/ http://investorsoup.com/2010/03/almealert/#comments Mon, 08 Mar 2010 14:32:52 +0000 Jeffrey Dean http://investorsoup.com/?p=4079 ALME is a small Oil Company Working Very Hard to Become a BIG Oil Company!

Good and Happy Monday Morning!

Say hello to:

Alamo Energy Corporation (ALME)

ALME, headquartered in London, England with offices in Houston, Texas, is an independent oil and gas exploration, development and production company that’s currently exploiting key oil and gas properties in both TEXAS and the UNITED KINGDOM.

How’s that for a twist!

I’ve never seen a junior oil and gas exploration company with such a diverse energy portfolio.  Here’s a quick summary of their oil properties:

In TEXAS:

ALME is currently running 13 wells across 590 acres. And it’s working hard to acquire additional Texas properties.

In ENGLAND:

ALME has interests in four onshore exploration blocks totaling 154 sq. miles. According to an independent geological report those blocks contain approximately 236 Million Barrels of oil!

Two items I want to emphasize…

1. ALME’s Texas properties are producing!

Not many junior oil companies can say that!

2. I’m waiting for their financials to be updated so I can see the magnitude of their cash flow—but the company is saying that whatever it is, it’s enough to fund operations and exploration on other properties.

Not many junior oil companies can say that either!

And another thing… a BIG thing!

Eurasian Capital Partners has agreed to invest up to $2,000,000 to support ALME’s business plan of expanding domestic production in Texas, Louisiana and Oklahoma.

Read the full story by clicking this link.

This capital investment is a huge validation of ALME’s potential!

ALME is a work in progress as you can see from the chart:

· The stock has had a short trading history, but it looks like support is developing at current levels

· Volume is intermittent (until the stock gets better known and develops a following)

· The MACD is still bullish and, with some increased buying interest, it could strengthen

· The stochastics has recently pulled out of oversold levels suggesting upside price action is possible.

ALME understands the importance of good PR!

The company is taking aggressive steps to promote themselves.

They’re constantly putting out positive news to get Wall Street to sit up and notice them (including news about their successful fund-raising efforts)

And they’re not shy about touting the fact that they’re actually pulling oil and gas out of the ground!

Do your Due Diligence and get ready to trade.

I would also encourage you to take a look at their corporate website.

Good luck and good trading,

Jeffrey Dean

Editor-in-Chief

——————————————————————————————————–

Newport Digital Technologies, Inc.  (NPDT)

NPDT, for the purposes of this blog, is primarily a chart play.  The company has yet to generate revenues, but from the PR’s it sure sounds like they are the  next Microsoft (jk).   They are a technology company allied with incubators in Taiwan and are creating products to match their competencies in WIMAX, RFID, Digital Signage, VOIP  and Security and Surveillance.  The technology is very interesting and has the potential to be HUGE.  Personally, I would like to see more PR’s touting sales, sales commitments, contracts, etc….

But, as a chart play, it might make sense.

I actually like the technology behind what NPDT is offering.  It recently announced that A WIMAX/RFID Alpha site is being brought online with a medical complex in Newport Beach, CA.  I will watch with interest to see how that goes and if it can be a springboard to other projects.  In the RFID arena, their goal is to replace bar codes and bar coding.

Here are some sites for your own due diligence:

Yahoo! Finance link

Company website

Good luck and good trading,

Jeffrey Dean

Editor-in-Chief

——————————————————————————————————————————————-

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Neither InvestorSoup.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Keryx Biopharmaceuticals Inc. (NASDAQ: KERX)

Keryx Biopharmaceuticals Inc. (KERX) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of life-threatening  diseases, including renal disease and cancer. The Company is developing Zerenex (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end stage renal disease (ESRD). KERX is developing KRX-0401 (perifosine), an oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 is in Phase 2 clinical development for multiple tumor types. KERX has strategic alliances with AEterna Zentaris Inc.; Panion & BF Biotech Inc.; Japan Tobacco Inc.; and Torii Pharmaceutical Co. Ltd. for the manufacture and commercialization of its products.

The Company was formerly known as Lakaro Biopharmaceuticals Inc. and changed its name to Keryx Biopharmaceuticals Inc. in January 2000. KERX was founded in 1998 and is based in New York, New York.

Source: Reuters.com, SEC Filings.

Financial Summary

At September 30, 2009, the Company had cash, cash equivalents, interest receivable and investment securities of $41.0 million, as compared to $22.7 million at December 31, 2008. On September 30, 2009, the Company completed a $20.0 million registered direct offering of common stock and warrants, which provided proceeds to the Company of approximately $18.4 million, net of offering costs of approximately $1.6 million, which were paid subsequent to September 30, 2009.

The net income for the third quarter ended September 30, 2009, was $0.6 million, or 1 cent per diluted share, compared to a net loss of $6.8 million, or 15 cents per diluted share, for the third quarter in 2008. The change in net income (loss) was primarily attributable to the recognition of $3.5 million in other revenue, related to the settlement of a dispute with the former licensor of Sulonex (sulodexide), in July 2009, over issues arising from the terminated license agreement, a $1.4 million decrease in other selling, general and administrative expenses, and a $1.4 million decrease in non-cash compensation expense related to equity grants.

The net income for the nine months ended September 30, 2009, was $15.1 million, or 31 cents per diluted share, compared to a net loss of $49.1 million, or $1.11 per diluted share, for the comparable period in 2008. The change in net income (loss) was primarily attributable to a $26.9 million decrease in research and development expenses related to the cessation of the development of Sulonex in March 2008, a $5.4 million decrease in research and development expenses related to KRX-0401 (perifosine), a $20.8 million increase in license revenue related to an amendment to the September 2007 sublicense agreement with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. (JT/Torii) that eliminated the Company’s significant ongoing obligations included in the original agreement ($18.0 million) and a $3.0 million milestone payment from JT/Torii earned in the first quarter of 2009, and a $3.6 million increase in other revenue primarily related to the settlement of a dispute for $3.5 million.

Source: Reuters.com, SEC Filings.

Analyst Consensus

This is the consensus forecast among 4 polled investment analysts. Against the Keryx Biopharmaceuticals Inc. company.

The 4 analysts offering 12-month price targets for KERX have a median target of 5.50, with a high estimate of 7.00 and a low estimate of 5.00. The median estimate represents a 105.99% increase from the last price of 2.67.

Source: www.ft.com

Consensus Estimates Analysis

Source: http://www.reuters.com/finance/stocks/financialHighlights?symbol=KERX.W

Investment Highlights

Zerenex (ferric citrate) is an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a U.S. Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and the Phase 3 clinical program of Zerenex is pending commencement under an SPA agreement with the FDA. Zerenex is also in Phase 2 development in Japan by the Company’s Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd.

KRX-0401 (perifosine) is a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, and a number of other key signal transduction pathways, including the JNK and MAPK pathways, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. The effects of KRX-0401 on Akt are of particular interest because of the importance of this pathway in the development of most cancers, with evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy, and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity. High levels of activated Akt (pAkt) are seen frequently in many types of cancer and have been correlated with poor prognosis.

To date, over 1,800 patients have been treated with KRX-0401 in trials conducted both in the United States and Europe. Its safety profile is distinctly different from that of most cytotoxic agents. KRX-0401 does not appear to cause flu-like symptoms, thrombocytopenia (decrease in platelets that may result in bleeding) or alopecia (hair loss); all of these toxicities occur frequently with many of the currently available treatments for cancer. The main side effects of KRX-0401 are nausea, vomiting, diarrhea and fatigue, but these are generally well-managed particularly at lower daily doses (50 mg or 100 mg) that have induced tumor regression. Responses have been seen with both daily and weekly regimens. At the doses studied, the daily regimens were better tolerated.

Product candidate	Target indication	Development status
KRX-0401 (perifosine)	Multiple myeloma Colorectal cancer Multiple other forms of cancer	Phase 3 ongoing, under SPA Phase 3 pending, under SPA Phase 2 trials ongoing
ZerenexTM (ferric citrate)	Hyperphosphatemia in patients with end-stage renal disease	U.S. Phase 2 complete; U.S. Phase 3 program pending; Japan Phase 2 ongoing by sublicensee (JT and Torii)

Source: http://www.keryx.com/page.cfm?hmid=&smid=&pg=main

Technical Analysis

Source: http://stockcharts.com

KERX is trading above its 13-day moving average. This is considered to be the sign of a bullish trend. There is added weight to this indication because the moving average is rising and suggests that there has been buying interest in this stock.

KERX is trading near its upper Bollinger Band. This suggests that the stock price is high relative to its recent price action.

The MACD for KERX currently indicates a strong bullish signal for two reasons. First, the MACD is above the signal line, a 9-day moving average. Second, the MACD is above 0, which implies that the underlying moving averages are trending higher.

Comparative Analysis

Source: Thomson Financial

Insider Trading Activity

NET SHARES PURCHASE ACTIVITY Inside Purchases - Last 6 Months
	Shares	Transaction
Purchases	10,000	1
Sales	22,981	1
Net Shares Purchased (Sold)	(12,981)	2
Total Insider Shares Held	7.46M	n/a
% Net Shares Purchased (Sold)	(0.2%)	n/a

Net Institutional Purchases - Prior Qtr to Latest Qtr
	Shares
Net Shares Purchased (Sold)	(12,748,300)
% Change in Institutional Shares Held	296.8%

Source: Yahoo Finance

Report Disclaimer

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

]]> http://investorsoup.com/2010/03/stock-alert-for-keryx-biopharmaceuticals-inc-kerx-2/feed/ http://investorsoup.com/2010/03/mcgi-is-a-shooting-star/ http://investorsoup.com/2010/03/mcgi-is-a-shooting-star/#comments Fri, 05 Mar 2010 17:03:38 +0000 Jeffrey Dean http://investorsoup.com/?p=4051 That will come crashing to earth soon!

MedCareers Group, Inc. (MCGI) has been a great story to watch over the past few days.  Lots of PR and a frothy stock price and some very impressive gains.  The question for me is it real and will it last?

It appears that it only became active recently after changing its name from RX Scripted, Inc. in early 2010.

They must have been saving up press releases because they have flooded the airwaves with several in rapid succession.  With the purchase of medcareers.com, they became Med Careers, Inc.  That book of business has been enhanced with the announcement of the purchase of two additional companies: Staff MD and workabroad.com.

It appears that they are in the online medical staffing business based upon the PR’s I’ve read.  The website gives some amorphous description of the business they are in. …that doesn’t really match their recent PR’s.

As you can tell, I am highly skeptical of their business. It seems like it is a phenomenon of some good PR and the expectation that this company is going to be a “player”.  The challenging thing is to put some kind of revenue and profits numbers to all this PR.  MCGI isn’t telling us, so I am assuming that the company is more sizzle than steak.

For as fuzzy as I think their website is, you can’t argue with this chart:

Note:  The issue is so new that my old charting standby, Stockcharts.com, hasn’t even listed MCGI in its database

Will this stock be a penny stock before it is a $5 stock?  I think so.

The Stochastics are very overbought, but until we get more trading history it is almost impossible to point to that indicator to say that it is going to fall.  What can they follow this hype up with?  Eventually traders will become numb to news about MCGI. Financial transparency, real revenues and profits will keep this stock afloat.  When the good news runs out, so will MCGI.

Good luck and good trading,

Jeffrey Dean

Editor

Oh, by the way:  The answer to the question I posed above (The question for me is it real and will it last?) is NO and NO!